• Unrivaled resolution of structural variations, rearrangements, and exon duplicates
• Flexible workflow
• Combined breadth and depth
• Designed for biomarker analysis in clinical trials, treatment monitoring, and acquisition of drug resistance with a single blood draw
Available in RUO and CLIA-validated assay
From a single sample, we provide low-pass whole genome sequencing (LP-WGS) data combined with broader coverage using WES and/or in-depth profiling using PredicineCARE™ or PredicineATLAS™ focused pan cancer panels, based on tumor fraction from the sample.
Whole blood
Plasma
Urine
FFPE
2-5 mL plasma
4-10 mL blood
20-40 mL urine
≥ 1mm³ tissue (5-10 FFPE slides)
10 days
We offer pilot program grants to select biopharma and academic partners to empower translational research and clinical studies. To initiate a study, contact us via the form below.
If you have any questions or need assistance, complete this form and we will respond within 24 hours.